Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03811951 · ClinicalTrials.gov registry record · Phase 2
Neuro Biomarkers of Smoking Behavior
A Phase 2 study, sponsored by University of Illinois at Chicago.
- Terminated
- Registry status
- Phase 2
- Development phase
- 4
- Enrollment target
NCT03811951 is a Phase 2 study that was terminated before completion, run by University of Illinois at Chicago. The registered enrollment target is 4 participants.
The verdict
NCT03811951, a Phase 2 study, was terminated before completion, sponsored by University of Illinois at Chicago.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 4 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate cognition in smokers and nonsmokers. It involves administration of intranasal insulin (Novolin R), an investigational medication followed by a brief non-invasive cognitive test. All participants will receive both Novolin R and placebo in two separate testing sessions.
Interventions
- DRUG Novolin R
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2018-09-12 |
| Est. Completion | 2019-09-27 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03811951
The ClinicalTrials.gov registry entry for NCT03811951 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 4 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Illinois at Chicago, which has 430 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Novolin R is the first listed.
NCT03811951 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03811951 about?
NCT03811951 is a clinical study titled "Neuro Biomarkers of Smoking Behavior". The purpose of this study is to evaluate cognition in smokers and nonsmokers. It involves administration of intranasal insulin (Novolin R), an investigational medication followed by a brief non-invasive cognitive test. All participants will receive both Novolin R and placebo in two separate testing ...
What is the current status of trial NCT03811951?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 4 participants. The study started on 2018-09-12. Estimated completion is 2019-09-27.
What interventions are being tested in trial NCT03811951?
The interventions under investigation include: Novolin R (DRUG).
Who is sponsoring clinical trial NCT03811951?
This trial is sponsored by University of Illinois at Chicago, which has 430 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.